Safety of the 9-Valent Human Papillomavirus Vaccine
- PMID: 31740500
- PMCID: PMC6935554
- DOI: 10.1542/peds.2019-1791
Safety of the 9-Valent Human Papillomavirus Vaccine
Abstract
Background: The 9-valent human papillomavirus vaccine (9vHPV) was approved for females and males aged 9 to 26 years in 2014. We analyzed postlicensure surveillance reports to the Vaccine Adverse Event Reporting System (VAERS).
Methods: We searched VAERS data for US reports of adverse events (AEs) after 9vHPV from December 2014 through December 2017. We calculated reporting rates and conducted empirical Bayesian data mining to identify disproportional reporting. Physicians reviewed reports for selected prespecified conditions.
Results: VAERS received 7244 reports after 9vHPV: 31.2% among females, 21.6% among males, and for 47.2%, sex was not reported. Overall, 97.4% of reports were nonserious. Dizziness, syncope, headache, and injection site reactions were most commonly reported; the most commonly reported AEs were similar between females and males. Two reports of death after 9vHPV were verified; no information in autopsy reports or death certificates suggested a causal relationship with vaccination. Approximately 28 million 9vHPV doses were distributed during the study period; crude AE reporting rates were 259 reports per million 9vHPV doses distributed for all reports and 7 per million doses distributed for serious reports. Syncope (a known AE associated with human papillomavirus vaccination) and several types of vaccine administration errors (eg, administered at wrong age) exceeded the statistical threshold for empirical Bayesian data mining findings.
Conclusions: No new or unexpected safety concerns or reporting patterns of 9vHPV with clinically important AEs were detected. The safety profile of 9vHPV is consistent with data from prelicensure trials and from postmarketing safety data of its predecessor, the quadrivalent human papillomavirus vaccine.
Copyright © 2019 by the American Academy of Pediatrics.
Conflict of interest statement
POTENTIAL CONFLICT OF INTEREST: Dr Arana currently works in Clinical Safety and Risk Management, Merck Research Laboratories, Merck & Co, on matters unrelated to the content of this article. During the time he worked on this article, he was employed by the Centers for Disease Control and Prevention. His work on the article ceased before his employment with Merck; the other authors have indicated they have no potential conflicts of interest to disclose.
Comment in
-
From Peyton Rous to the HPV Vaccine: A Journey of Discovery and Progress.Pediatrics. 2019 Dec;144(6):e20192345. doi: 10.1542/peds.2019-2345. Epub 2019 Nov 18. Pediatrics. 2019. PMID: 31740499 No abstract available.
Similar articles
-
Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020.J Infect Dis. 2022 Oct 21;226(Suppl 4):S431-S440. doi: 10.1093/infdis/jiac306. J Infect Dis. 2022. PMID: 36265846 Review.
-
Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016.Vaccine. 2020 Sep 11;38(40):6291-6298. doi: 10.1016/j.vaccine.2020.07.039. Epub 2020 Jul 31. Vaccine. 2020. PMID: 32747215 Free PMC article. Review.
-
Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017.Vaccine. 2019 Feb 21;37(9):1229-1234. doi: 10.1016/j.vaccine.2018.11.077. Epub 2019 Jan 16. Vaccine. 2019. PMID: 30660400 Free PMC article.
-
Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.Vaccine. 2018 Mar 20;36(13):1781-1788. doi: 10.1016/j.vaccine.2018.02.034. Epub 2018 Feb 21. Vaccine. 2018. PMID: 29477308
-
Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.JAMA. 2009 Aug 19;302(7):750-7. doi: 10.1001/jama.2009.1201. JAMA. 2009. PMID: 19690307
Cited by
-
Can prophylactic HPV vaccination reduce the recurrence of cervical lesions after surgery? Review and prospect.Infect Agent Cancer. 2023 Oct 29;18(1):66. doi: 10.1186/s13027-023-00547-2. Infect Agent Cancer. 2023. PMID: 37898754 Free PMC article. Review.
-
Barriers to human papillomavirus vaccine uptake: role of state religiosity and healthcare professionals' participation in a state vaccine program.JNCI Cancer Spectr. 2023 Aug 31;7(5):pkad068. doi: 10.1093/jncics/pkad068. JNCI Cancer Spectr. 2023. PMID: 37698997 Free PMC article.
-
Updates in Cervical Cancer Screening Guidelines, The Bethesda System for Reporting Cervical Cytology, and Clinical Management Recommendations.J Clin Transl Pathol. 2023 Jun;3(2):75-83. doi: 10.14218/jctp.2023.00004. Epub 2023 Apr 21. J Clin Transl Pathol. 2023. PMID: 37456763 Free PMC article.
-
Recurrent Respiratory Papillomatosis (RRP)-Meta-analyses on the use of the HPV vaccine as adjuvant therapy.NPJ Vaccines. 2023 Apr 1;8(1):49. doi: 10.1038/s41541-023-00644-8. NPJ Vaccines. 2023. PMID: 37005390 Free PMC article.
-
Human papillomavirus vaccine initiation and up-to-date vaccine coverage for adolescents after the implementation of school-entry policy in Puerto Rico.PLOS Glob Public Health. 2022 Nov 8;2(11):e0000782. doi: 10.1371/journal.pgph.0000782. eCollection 2022. PLOS Glob Public Health. 2022. PMID: 36962595 Free PMC article.
References
-
- Merck & Co, Inc. Gardasil 9 [Package Insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2014
-
- Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016; 65(49):1405–1408 - PubMed
-
- Petrosky E, Bocchini JA Jr, Hariri S,et al.; Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2015; 64(11):300–304 - PMC - PubMed
-
- Markowitz LE, Dunne EF, Saraiya M,et al.; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Recomm Rep. 2014;63(49):1182]. MMWR Recomm Rep. 2014;63(RR):1–30 - PubMed
-
- US Food and Drug Administration. Gardasil 9 [approval letter]. 2018. Available at: www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/U.... Accessed July 23, 2019
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources